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Abstract
Background: Presented here are the results of a comparative trial on the efficacy of three
artemisinin-based combinations conducted from May to October 2004, in Pool Province, Republic
of Congo.
Methods: The main outcome was the proportion of cases of true treatment success at day 28.
Recrudescences were distinguished from re-infections by PCR analysis. A total of 298 children of
6–59 months were randomized to receive either artesunate + SP (AS+SP), artesunate +
amodiaquine (AS+AQ) or artemether + lumefantrine (AL), of which 15 (5%) were lost to follow-up.
Results: After 28 days, there were 21/85 (25%) recurrent parasitaemias in the AS+SP group, 31/
97 (32%) in the AS+AQ group and 13/100 (13%) in the AL group. The 28-day PCR-corrected cure
rate was 90.1% [95% CI 80.7–95.9] for AS+SP, 98.5% [95% CI 92.0–100] for AS+AQ and 100%
[95.8–100] for AL, thereby revealing a weaker response to AS+SP than to AL (p = 0.003) and to
AS+AQ (p = 0.06). A potential bias was the fact that children treated with AL were slightly older
and in better clinical condition, but logistic regression did not identify these as relevant factors.
There was no significant difference between groups in fever and parasite clearance time,
improvement of anaemia and gametocyte carriage at day 28. No serious adverse events were
reported.
Conclusion: Considering the higher efficacy of AL as compared to AS+SP and the relatively high
proportion of cases with re-infections in the AS+AQ group, we conclude that AL is clinically more
effective than AS+SP and AS+AQ in this area of the Republic of Congo. Implementation of the
recently chosen new national first-line AS+AQ should be monitored closely.
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Background
In the Republic of Congo (RoC), malaria is the leading
cause of morbidity and mortality in children under five
years of age and the main reason for hospitalization. The
total population of the country, totalling 3.2 million, is at
risk of year-round highly endemic malaria. The percentage
of medical consultations due to malaria is 30 to 50%
[1,2]. According to the National Malaria Programme of
the Ministry of Health, Plasmodium falciparum is responsi-
ble for 98% of malaria cases. The malaria incidence has
increased over the past years, as a result of the deteriora-
tion of the health infrastructure and population move-
ments during the country's recent episodes of conflict on
the one hand and due to rising levels of resistance to com-
mon antimalarials on the other hand.
Chloroquine (CQ) was still the national recommended
first-line and sulfadoxine-pyrimethamine (SP) the second
line for uncomplicated falciparum malaria in 2004, at the
time of study. Most recent data on drug efficacy have indi-
cated a resistance as high as 90% against CQ and 25%
against SP, and this was in a 14-day sentinel survey with-
out PCR to identify new infections [3]. This seems to have
rapidly increased since earlier data from 1999–2002
showed CQ resistance of 38–50% and SP resistance 0–
10% [4,5]. Amodiaquine (AQ) resistance was also quite
high in the few reported studies: 23% [6] and 21% in
Brazzaville at day 7 [7].
The health authorities in the RoC were, at the time, pre-
paring to change the national antimalarial treatment pro-
tocol, but still had to make a choice for the best suitable
therapy. In most African countries, the first-line therapy
has been revised recently and; at the time of writing, a
total of 33 countries have chosen to implement artemisi-
nin combination therapy or ACT, although only 14 have
actually commenced implementation [8].
Here, we investigated the efficacy of three ACTs, that were
considered potential new first-line therapies for the coun-
try, namely artesunate (AS) + SP, AS + AQ and artemether-
lumefantrine (AL), in Pool Province in the southeast of
RoC.
Patients and methods
Study location
Kindamba is the principal town of Kindamba district in
the South of the RoC, located in Pool province (Figure 1).
This is a heavily malaria-infested area, which was also the
main battleground during the periods of internal conflict
during the past decade. The security situation improved
since the beginning of 2004 making it possible to execute
a proper malaria drug efficacy trial (except for a three-
week unsafe period when only a skeleton team remained
for follow-up of study-patients, no new cases were
enrolled). The population of Kindamba Health Zone was
estimated at 20,000 but has increased with the improving
security situation. Malaria tends to be holo-endemic the
whole year through. The season for malaria is bimodal in
the south, with a peak at the end of both rainy seasons
from March to May and late September to December.
The health centre where the study was based is the Kin-
damba Centre de Santé Intégré, supported by MSF since
2003. This clinic saw about 500 to 600 cases each month
of laboratory-confirmed malaria cases in 2004. The pro-
portionate malaria morbidity among outpatients aver-
aged to about 45% in the under 5's and 30% in older age-
groups, while this was over 70% and 40% of in-patients
for the two age groups, respectively.
Study design
The standard WHO protocol for in vivo drug efficacy stud-
ies in areas of high transmission was followed [9]. Briefly,
all children between 6 and 59 months of age presenting
with fever (37.5°C or above) or a history of fever within
the past 24 hours and a P. falciparum mono-infection with
density between 2,000 and 200,000 parasites per μl were
included in the trial. Written informed consent was asked
from the care-taker of the child. Excluded were cases pre-
senting with one or more general danger signs or signs of
severe or complicated malaria [10], a serious concomitant
illness, malnutrition or a known hypersensitivity to one of
the study drugs, and those living further than 2 hours
walking distance. In addition, children weighing less than
10 kg were not included in the group treated with AL, in
accordance with then existing prescription guidelines in
2004. For the other two treatment groups weight limits
were set at 5 kg, considered a minimum weight for 6
month-old infants.
Children were enrolled in the study and randomly
assigned to one of three therapies: (1) AS + SP: single dose
SP on the first day (Fansidar®, La Roche, France; 25 mg S
and 1.25 mg P per kg) and 3-day AS (Arsumax®, Sanofi,
France; 4 mg/kg body-weight per day), (2) AS + AQ 3-day
AQ (Camoquin®, Parkes Davis/Pfizer, UK, 10 mg/kg per
day) and AS (4 mg/kg per day) and (3) AL fixed combina-
tion (Coartem®, 20 mg arthemeter + 120 mg lumefan-
trine, Novartis Pharma, Switzerland). The dosage of AL
(twice daily for three days) depended on body weight and
followed the manufacturer instructions. All were treated
orally under supervision in the clinic. However, in the AL
group, for patients that were unable to stay or to come
back to the clinic in the evening, the second daily dose was
taken at home and observed by village fieldworkers who
visited the patient at the time of treatment. At each dose,
AL was given with some fatty food or a glass of milk.
When a child was assigned to AL but weighed below 10Malaria Journal 2006, 5:113 http://www.malariajournal.com/content/5/1/113
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kg, the next possible treatment allocation was given and
AL was given to the following study patient.
Patients were asked to come back for treatment the fol-
lowing 2 days and for follow-up visits on day 3, 7, 14, 21
and 28. They were clinically examined at all visits, both to
check for signs of illness as for potential side-effects of
treatment, as passively reported to the medical responsi-
ble, and had their blood-film taken on all these occasions
except day 1. Blood films (thin and thick smears) were
stained by Giemsa and examined by experienced micro-
scopists. A quantitative parasite count of asexual forms
Flow chart drug efficacy trial Figure 1
Flow chart drug efficacy trial.
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was performed for positive cases (using the parasite/White
Blood Cell Count) and the presence of gametocytes was
noted. Based on clinical and laboratory findings, cases
were classified as early treatment failures (ETF), late clini-
cal failures (LCF), and late parasitological failures (LTF) or
adequate clinical and parasitological responders (ACPR,
see WHO 2003c). The final outcome parameter of the effi-
cacy trial was the cure rate at the end of the follow-up
period of 28 days in each of the three treatment arms. A
true failure was defined as a recrudescence defined by PCR
analysis eliminating re-infections. Haematological recov-
ery was assessed by haemoglobin measurements (using
the Hemocue®, Ängelholm, Sweden) before and after
treatment. The rescue treatment in case of failure was qui-
nine for 7 days.
The PCR genotyping used for distinguishing recrudes-
cences and re-infections was performed at the laboratory
of the Shoklo Malaria Research Unit, Thailand, based on
a previously described protocol [11], comparing the P. fal-
ciparum msp-1, msp-2 and glurp gene loci of pre- and post-
treatment sample pairs. The outcome of treatment with
PCR correction was based on the number of true recrudes-
cences, excluding cases of novel infections or indetermi-
nate PCR from analysis (as per protocol [9]).
Laboratory quality control was carried out on 10% of the
slides by qualified laboratory experts working in laborato-
ries within the other MSF projects in the country (Kinkala,
Nkayi, Moussaka). Slides were read blindly, and results
were compared afterwards with those from the study lab-
oratory. Data analysis was performed using Excel database
and SPSS software. We used χ2 tests to compare categorical
data (Fisher exact for groups smaller than n = 5). Contin-
uous data were tested for normality (Test for Skewness,
Shapira – Wilkoxon Test for Normality). Normally dis-
tributed data were analysed with T-tests and ANOVA, and
not-normally distributed data with Ranksum tests. Multi-
variate regression analysis was performed to determine
whether baseline characteristics were associated with the
outcome of treatment. Age, weight, temperature and par-
asite density were entered into the model as linear varia-
ble or classified in 3 to 5 categories and haemoglobin level
in 3 classes: moderate (5–7.9 g/dl), mild (8–10.9 g/dl) or
no anaemia.
Ethical approval
The protocol received ethical clearance from the RoC Min-
istry of Health of the Republic of Congo and the external
Ethical Review Board used by MSF. The necessary permis-
sion from the local authorities (Sous-préfet and hospital
senior staff) in Kindamba, Pool District of study was
obtained.
Results
Baseline characteristics
From 27 May to 6 October 2004, a total of 298 children
were enrolled in the study and 101 children received
AS+AQ, 91 received AS+SP and 106 received AL.
Due to the different weight-entry criteria for AL (≥10 kg)
as compared to the other two ACT groups (≥5 kg), the
children in the three treatment groups were not equal for
all basic demographic characteristics on admission. There
was a significant difference in weight, age, MUAC and
blood haemoglobin value between the AL group and the
other two groups. 36.5% of children were below 2 years;
the average age was 27 months (Table 1).
The results of the external quality control of 300 slides
revealed no disagreements in presence/absence of P. falci-
parum  parasites. There were 4 slides that had different
findings for P. falciparum gametocytes and in one slide the
reference laboratory reported the presence of Plasmodium
ovale parasites. None of these disagreements, nor some
discrepancies found in parasite densities, changed the out-
come of the treatment.
In total, 282 patients reached the study endpoint (94.6%),
11 were lost to follow-up (due to migration out of the
area) and 5 were secondary exclusions (1 was retreated
while not (yet) a failure, 4 were given drugs at home with
antimalarial activity during follow-up; see Figure 2). There
was no significant difference between the cases lost to fol-
low-up or withdrawn in the groups AS + AQ (4%, 4/101),
AS + SP (7%, 6/91) and AL (6%, 6/106, P = 0.42).
Primary treatment outcome
The proportion of recurrent parasitaemia's during the 4-
week follow-up was higher in the AS+AQ group (32.0%;
31/97), and AS+SP group (24.7%; 21/85) than in the AL
group (13.0%; 13/100). No ETF's were observed in any of
the three treatment groups.
A total of 57 patients were excluded after PCR analysis.
From the 65 patients eligible for PCR analysis, only 50
PCR were performed (15 samples not taken during a secu-
rity evacuation of part of the study team). Among these,
only 38 had a PCR result available (12 indeterminate
results), of which 30 were re-infections which were
excluded from the final analysis (Table 2; Figure 2). The
proportion of re-infections was 18% (17/97) in the
AS+AQ group, 11% (9/85) in the AS+SP group and 4% (4/
100) in the AL group. The re-infection rate after AS+AQ
treatment was significantly higher than after AL (p =
0.002).
At day 28, the AS+AQ group showed a cure rate of 98.5
[95% CI 92.0–100], the AS+SP group 90.1% [95% CIMalaria Journal 2006, 5:113 http://www.malariajournal.com/content/5/1/113
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80.7–95.9] and the AL group 100.0% [95% CI 95.8–
100.0]. The cure rate of the AS+SP group was lower than
that of the AL treatment (p = 0.003), and AS+AQ (p =
0.06) whereas differences in efficacy between AL and
AS+AQ were not significant (p = 0.4).
Cases of recrudescence as well as cases of re-infection
occurred at a relatively long time interval after treatment
in all three groups. The median time to recurrent parasi-
taemia was 21 days for the AS+AQ group, 21 for AS+SP
and 28 for AL.
Multivariate regression analysis showed that for 'recurrent
parasitaemia', none of the baseline characteristics age, sex,
weight initial parasite count, temperature or haemoglobin
level influenced the outcome significantly; independent
of these, the treatment group was the primary determi-
nant of recurrent parasitaemia at day 28. For the recrudes-
cent cases (PCR corrected true failure rates), multiple
factorial analysis was not possible, due to the low num-
bers of failures.
Secondary treatment outcomes
On inclusion, 178/298 (60%) of patients had measured
fever. The axillary temperature decreased rapidly after all
three therapy regimens. At day 3, the number of febrile
patients was similarly low in each arm (ASAQ = 3/101,
Map of the Republic of Congo showing the location of the  study site, Kindamba, in Pool Province Figure 2
Map of the Republic of Congo showing the location of the 
study site, Kindamba, in Pool Province.
Kindamba
Table 1: Baseline characteristics of study participants, Kindamba, ROC 2004
AS + AQ AS + SP Coartem Total P-value
Number of patients
(% of total)
101 (33.9) 91 (30.5) 106 (35.6) 298
Sex: F/M (% F) 46/55 (45.5) 38/53 (41.8) 50/56 (47.2) 134/164 (45.0) P = 0.74
Age* (months) 20.5 ± 10.7 (7–48) 23.0 ± 11.9 (6–54) 36.1 ± 11.1 (12–59) 26.8 ± 13.2 (12–59) P < 0.001
Weight*(Kg) 9.7 ± 2.3 (6–16) 10.1 ± 2.4 (5–19) 12.7 ± 2.0 (10–20) 10.9 ± 2.6 (5–20) P < 0.001
MUAC* (mm) 142.5 ± 13.8 (112–180) 143.5 ± 11.8 (100–188) 151.5 ± 10.6 (130–190) 146.1 ± 12.7 (100–190) P < 0.001
Haemoglobin*
(g/dl)
8.8 ± 1.7 (5.0–12.8) 9.1 ± 1.7 (5.1–12.3) 9.6 ± 1.7 (5.1–14.2) 9.2 ± 1.7 (5.0–14.2) P = 0.003
Moderate anaemia ‡
(Hgb 5 < 8 g/dl)
30 (29.7) 25 (27.5) 16 (15.2) 71 (23.9) P = 0.03
Mild anaemia ‡
(Hgb 8 < 11 g/dl)
59 (58.4) 53 (58.2) 66 (62.9) 178 (59.9) P = 0.80
Temperature *(°C) 38.0 ± 1.2 (35.8–40.0) 37.8 ± 1.3 (34.8–40.7) 37.9 ± 1.3 (34.8–40.7) 37.9 ± 1.3 (34.8–40.7) P = 0.320
Parasite density**
(per μl)
28,941 (2040–200,000) 24,997 (1200–200,000) 23,997 (2000–200,000) 25,890 (1200–200,000) P = 0.651
Gametocytes ‡ 23 (22.8) 24 (26.4) 9 (8.5) 56 (18.8) P = 0.003
* Values given as mean ± SD (Standard Deviation) and range (min-max value),
** Parasite density given as geometric mean and range.
‡ Anaemia/gametocytemia described by number + proportion of cases with anaemia/gametocytes.Malaria Journal 2006, 5:113 http://www.malariajournal.com/content/5/1/113
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ASSP = 4/90, AL = 8/105). All children were parasite free
on day 3.
The proportion of cases with gametocytes increased dur-
ing the first two days of treatment, but overall reduced
during the four weeks of follow-up, from 23% to 3% in
the AS+AQ group, from 26% to 5% in the AS+SP group
and from 8% to 1% in the AL group (Figure 3).
There was a clear increase in the average haemoglobin lev-
els in the three treatment groups during the 28 days of fol-
low-up (Figure 4). Overall, the percentage of cases with
moderate anaemia (5–7.9 g/dl) reduced from 23.9% at
enrolment to 4.2%, while the proportion mildly anaemic
(Hgb 8–10.9 g/dl) was still relatively high at the end of
study, 61.9% compared to baseline 59.9%.
There were no clinically severe adverse events related to
the treatment given. The most frequent complaints during
the three days of treatment were vomiting, diarrhoea,
abdominal pain and anorexia. The frequency of these
potential treatment-related signs and symptoms was low
(around 10% of children) and did not differ among the
three treatment groups. There were two cases of urticaria,
one after AS+SP and one after AS+AQ treatment, but these
developed after completion of the treatment, so it was not
necessary to stop or interrupt the treatment.
Discussion
The study presented here shows that in the Pool region,
Republic of Congo, AS+SP, AS+AQ and AL, are effective to
treat uncomplicated P. falciparum. This is one of the first
studies on ACTs in this country. AL is the most efficacious
one of the three (100% with 95% CI 96–100); none of the
children receiving this therapy had a recrudescent infec-
tion in the 4 weeks of follow-up. AS+SP showed a signifi-
cantly lower efficacy than AL (90% with 95% CI 87–96),
and AS+AQ (98.5 with 95% CI 92–100). The secondary
outcomes of rapid fever-, parasite- and gametocyte clear-
ance and the beneficial effect on blood haemoglobin lev-
els were similar for the three therapies.
However, a substantially large proportion of children
showed a recurrent parasitaemia in 4 weeks after treat-
ment: 32% in the AS+AQ group, 25% in the AS+SP group
and 13% in the AL group. AL appeared to prevent re-infec-
tion better than AS+AQ. Infection rates can be assumed
equal among the treatment groups. AS is cleared from the
blood within hours, so any protective effect of combina-
tion therapy comes from the remaining drug levels of AQ,
SP and lumefantrine. Higher re-infection rates may be
related to reduced AQ susceptibility/developing resistance
of the parasites.
The interpretation of PCR analysis should be taken cau-
tiously. Re-infections were confirmed in 46% of the recur-
rent infections, but there was a substantial part of PCR
results unavailable (42% or 27/65), due to missing sam-
ples and indeterminate results. The available PCR results
indicate that about 20% of recurrent infections were
recrudescences; applying this 'rule' to the missing values,
we calculated failure rates of 6% for AS+AQ (3 extra recru-
descent cases assumed from 13 missing cases), 11% for
AS+SP (1 added of 5 missing cases) and 2% for AL (2
added of 9 cases).
The treatment allocation was randomized, however, the
specific entry criteria of weight for the AL group (above 10
kg) may have influenced the outcome of the study. The
children selected for treatment with AL were on average
older, and healthier. This group therefore may have had a
better general condition and probably acquired some
Table 2: Proportion of recurrent parasitaemia and treatment failures at 28 days after treatment, Kindamba, ROC, 2004
AS + AQ AS + SP AL χ2
n % 95% CI n % 95% CI n % 95% CI P
No PCR 97 85 100
ACPR 66 68.0 57.8–77.1 64 75.3 64.7–84.0 87 87.0 78.8–92.9 0.006
Parasites/fever 19 19.6 12.2–28.9 9 10.6 5.0–19.1 5 5.0 1.6–11.3
Parasites/no fever 12 12.4 6.6–20.6 12 14.1 7.5–23.4 8 8.0 3.5–15.2
Recurrent parasitaemia 31 32.0 22.9–42.2 21 24.7 16.0–35.3 13 13.0 7.1–21.2 0.006
PCR adjusted 67 71 87
ACPR 66 98.5 92.0–100 64 90.1 80.7–95.9 87 100.0 95.8–100 0.003
LCF 0 0.0 0–5.4 2 2.8 0.3–9.8 0 0.0 0–4.2
LPF 1 1.5 0–8.0 5 7.0 2.3–15.7 0 0.0 0–4.2
Treatment failure 1 1.5 0.0–8.0 7 9.9 19.3–4.1 0 0.0 0.0–5.2 0.003Malaria Journal 2006, 5:113 http://www.malariajournal.com/content/5/1/113
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immunity against malaria, preventing rapid recrudes-
cence, leading to a higher measured efficacy of AL. We had
to follow the AL prescription criteria for ethical reasons,
but maintained the usual weight limit for the other two
treatment arms, to keep this study comparable to others in
the region. The limitation of weight for AL has now been
lowered from 10 kg to 5 kg in December 2004 by WHO
[12,13].
The true failure rates may have been higher. Treatment
failures can occur more than 28 days after treatment. It has
been estimated [14] that 28-days assessments underesti-
mate the true failure by about 20% for drugs with inter-
mediate elimination half-life, such as lumefantrine and
SP (3–6 days half-life [15]), and as much as 40% for drugs
with a longer elimination half-life, such as desethylamo-
diaquine, the active metabolite that AQ quickly metabo-
lises into (one to three weeks half-life [16]).
The levels of efficacy compare to findings from other
recent studies on ACTs in surrounding in southwest
Africa. In Angola, AL, AS+AQ and AS+SP were found to be
highly effective [17]. In DRC, somewhat lower efficacy
levels were found for AS+AQ, ranging from 81% to 93%
while the findings for AS+SP were similar in one site, but
lower, 67%-80% in other [18]. In Gabon, AS+AQ showed
a 85% efficacy [19]. AL has shown a high efficacy where
tested in Africa, in the range 94–100% [4,12,20].
Artemether-lumefantrine has shown more consistent effi-
cacy to treat uncomplicated falciparum malaria than the
other two ACTs in the study area in Congo Republic, and
this is reflected by studies in the neighbouring countries as
well. A careful implementation of AL is, therefore, recom-
mended as the new protocol.
However, recent decisions at the National Malaria Pro-
gramme in Brazzaville point towards AS + AQ as the new
first-line antimalarial treatment, described for use at
household as well as health centre level with basic symp-
tomatic diagnosis (draft document PNLP). The second-
line treatment defined is AL (or quinine or artemether)
based on microscopy diagnosis.
Gametocytaemia per treatment group during follow-up Figure 3
Gametocytaemia per treatment group during follow-up.
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Malaria is a high burden on health expenditures in
Congo, a country with an infection prevalence estimated
at 50% or more [21], leading to an incidence of about one
episode per year in children < 15 years old [22]. The price
of AL as compared to AS + AQ has probably played a sig-
nificant role in the decision-making, as well uncertainties
on the availability of AL at large scale. Congo is a low-
income country and close to 50% of the people live under
the limit of poverty (1 US$ per day), so the increase in cost
of antimalarial treatment with the introduction of ACT
cannot depend on patient fees. Treatment should be pro-
vided at subsidized cost from government health facilities,
and external funding will be needed to realize that. In
addition, the country has a largely urban population: 60%
of the people live in town, the majority in Brazzaville and
Pointe Noire. For this group 'formal public health facili-
ties are often the last source of treatment used along the
pathway to cure' [23] and this poses additional challenges
to deliver a new ACT therapy and impose correct prescrip-
tion.
Conclusion
Implementation of the new RoC anti-malarial policy
should be accompanied by adequate population sensitisa-
tion and facilitation of clear prescriptions using available
blister-packaging or co-formulation, to prevent misuse of
valuable medication risking further development of AQ
resistance. The efficacy of the artemisinin combination
therapies should be monitored at 2-year intervals after
implementation.
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Haemoglobin values measured at 2-weekly visits in the three treatment groups Figure 4
Haemoglobin values measured at 2-weekly visits in the three treatment groups.
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